1. Home
  2. KINS vs IMRX Comparison

KINS vs IMRX Comparison

Compare KINS & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KINS

Kingstone Companies Inc.

HOLD

Current Price

$19.91

Market Cap

291.4M

Sector

Finance

ML Signal

HOLD

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$4.32

Market Cap

265.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KINS
IMRX
Founded
1886
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
291.4M
265.3M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
KINS
IMRX
Price
$19.91
$4.32
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$17.20
AVG Volume (30 Days)
149.1K
1.3M
Earning Date
05-07-2026
05-04-2026
Dividend Yield
1.18%
N/A
EPS Growth
94.59
37.75
EPS
N/A
N/A
Revenue
$214,867,301.00
N/A
Revenue This Year
$24.23
N/A
Revenue Next Year
$18.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
38.50
N/A
52 Week Low
$13.08
$2.90
52 Week High
$20.79
$10.08

Technical Indicators

Market Signals
Indicator
KINS
IMRX
Relative Strength Index (RSI) 58.28 38.87
Support Level $14.37 $3.95
Resistance Level $20.79 $5.36
Average True Range (ATR) 0.70 0.27
MACD -0.22 -0.09
Stochastic Oscillator 51.03 3.15

Price Performance

Historical Comparison
KINS
IMRX

About KINS Kingstone Companies Inc.

Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: